• CD28-costimulated CAR signaling mutants for increased anti-tumour activity and persistence

    Posey AD, Guedan S. Priority date: 2018. Granted. Licensed to Novartis.

  • Combination Therapy using Chimeric Antigen Receptors

    June CH, Watanabe K, Guedan S, Hemminki A, Scholler J, Young R. WO2019152660A1. Priority date: 2018.

  • Oncolytic adenoviruses for treating cancer

    Guedan S, Cascallo M, Alemany A. Patent Number: US 2012/8535A1. Priority date: 2009. Granted. Licensed to VCN Biosciences

  • Subset-optimized chimeric antigen receptor-containing T-cells

    June CH, Guedan S, Posey AD, Scholler J. Application number: WO2016019300A1. Priority date: 2014. Granted. Licensed to Tmunity Therapeutics.

  • Use of ICOS-Based CARs to Enhance Antitumour Activity and CAR Persistence

    June CH, Guedan S, Xhao Y, Scholler J. Patent Number: US 2015/0017141A1. Priority date: 2012. Granted. Licensed to Novartis.